Development of a Highly-Sensitive Targeted Cell-Free DNA Epigenomic Assay for Early-Stage Multi-Cancer Screening

A blood-based cancer screening test should exhibit performance metrics optimized for the cancer of interest…

Back to Blog Listing

Sign up to receive the latest updates on Shield^TM

Email address

Please enter a valid email address.

By clicking the button above, you agree to receive periodic product-related updates via email from Guardant Health.

Guardant Health press release ECLIPSE trial on ClinicalTrials.gov

Compliance

in real-world clinical settings for colorectal cancer (CRC) screening¹*

Proven accuracy in the pivotal ECLIPSE^† trial, with 83% sensitivity and 90% specificity^2‡§

One of the largest studies and first of its kind to validate a blood test that detects CRC³

The future of CRC screening starts now. Go

*Compliance rate for the first 8,000 patients that were prescribed Shield and completed it.¹

^†The ECLIPSE study (NCT04136002) is comparing the sensitivity and specificity of cfDNA only Shield with findings from subsequent colonoscopy in over 10,000 average-risk patients.^1,2
^‡Specificity detected for advanced neoplasia defined in ECLIPSE as CRC or advanced adenomas.^1,3
^§Patients had no prior diagnosis of CRC, inflammatory bowel disease, or family history of genetic risk for CRC (eg, Lynch syndrome).³

References: 1. Data on file. Guardant Health, Inc. 2. Guardant Health press release. December 15, 2022. 3. ECLIPSE trial on ClinicalTrials.gov

Share this page:

Development of a Highly-Sensitive Targeted Cell-Free DNA Epigenomic Assay for Early-Stage Multi-Cancer Screening

Sign up to receive the latest updates on ShieldTM

Sign up to receive the latest updates on Shield^TM